HomeCompareCDTX vs VICI

CDTX vs VICI: Dividend Comparison 2026

CDTX yields 0.90% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VICI wins by $945.3K in total portfolio value
10 years
CDTX
CDTX
● Live price
0.90%
Share price
$221.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.0K
Annual income
$95.80
Full CDTX calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — CDTX vs VICI

📍 VICI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDTXVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDTX + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CDTX pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDTX
Annual income on $10K today (after 15% tax)
$76.79/yr
After 10yr DRIP, annual income (after tax)
$81.43/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $516,188.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDTX + VICI for your $10,000?

CDTX: 50%VICI: 50%
100% VICI50/50100% CDTX
Portfolio after 10yr
$493.6K
Annual income
$303,735.96/yr
Blended yield
61.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

CDTX
Analyst Ratings
1
Strong
7
Buy
3
Hold
Consensus: Buy
Price Target
$181.50
-18.0% upside vs current
Range: $150.00 — $221.50
Altman Z
32.6
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDTX buys
0
VICI buys
0
No recent congressional trades found for CDTX or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDTXVICI
Forward yield0.90%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$21.0K$966.2K
Annual income after 10y$95.80$607,376.13
Total dividends collected$933.00$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$181.50$31.60

Year-by-year: CDTX vs VICI ($10,000, DRIP)

YearCDTX PortfolioCDTX Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$10,790$90.34$11,361$941.49$571.00VICI
2$11,637$91.11$13,320$1,481.32$1.7KVICI
3$12,543$91.82$16,284$2,405.01$3.7KVICI
4$13,514$92.50$21,040$4,071.78$7.5KVICI
5$14,553$93.14$29,209$7,285.49$14.7KVICI
6$15,665$93.74$44,443$14,006.51$28.8KVICI
7$16,856$94.30$75,822$29,512.55$59.0KVICI
8$18,131$94.83$148,733$69,726.75$130.6KVICI
9$19,495$95.33$344,394$189,413.75$324.9KVICI
10$20,956$95.80$966,234$607,376.13$945.3KVICI

CDTX vs VICI: Complete Analysis 2026

CDTXStock

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Full CDTX Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this CDTX vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDTX vs SCHDCDTX vs JEPICDTX vs OCDTX vs KOCDTX vs MAINCDTX vs NNNCDTX vs EPRTCDTX vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.